Related Experiment Video
Updated: Jan 16, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Sex-Specific Outcomes of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation: Results From the
Molly Szerlip1, Linda D Gillam2, D Scott Lim3
1Department of Cardiology, Baylor Scott and White: The Heart Hospital Plano, Plano, Texas.
Background:
Female patients with degenerative mitral regurgitation (DMR) can have worse mitral valve repair outcomes. We aim to study sex-specific differences in contemporary mitral transcatheter edge-to-edge repair (M-TEER).
Methods:
One-year outcomes in prohibitive surgical risk patients with 3+/4+ DMR from the randomized CLASP IID trial were analyzed by sex.
Results:
The analysis population comprised 34.7% female patients (n = 102) and 65.3% male patients (n = 192). Female patients had significantly lower body mass index, fewer comorbidities, and smaller left ventricular indexed volumes and mitral valve area at baseline. At 1 year, there were no significant differences between female and male patients in survival (92.1% vs 90.9%, P = .754), freedom from heart failure hospitalization (91.7% vs 94.4%, P = .366), and freedom from major adverse events (86.0% vs 85.9%, P = .985), respectively. Both sexes achieved a significant reduction in mitral regurgitation from baseline at 1 year (P < .001), with comparable mitral regurgitation ≤1+ (75.6% vs 75.0%, P = 1.000). Baseline-adjusted changes in indexed left ventricular volumes (diastolic: -18.8 vs -15.7 mL, P = .087; systolic: -5.6 vs -5.0 mL, P = .645) and mitral gradients (+1.4 vs +1.1 mm Hg, P = .116) were similar, with no indication of stenosis. New York Heart Association class I/II was achieved in 86.4% of female patients vs 88.7% of male patients (P = .674), and the Kansas City Cardiomyopathy Questionnaire overall score increased by 14.1 vs 15.8 points (P = .502), respectively.
Conclusions:
In the CLASP IID randomized trial, both sexes experienced high survival and freedom from major adverse events and heart failure hospitalization at 1 year post-M-TEER, with comparable improvements in echocardiographic, functional, and quality-of-life measures, despite differences in clinical presentation and the procedure. Results demonstrate that female patients achieve favorable safety and effectiveness outcomes, comparable to male patients, with contemporary M-TEER in DMR.
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Regurgitation I: Introduction
Mitral Valve Prolapse II: Assessment and Management

